Project Grant R01HL179112
- This Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), will fund the development of novel computational methods to investigate the role of DNA methylation in the progression of Chronic Obstructive Pulmonary Disease (COPD). The $1,470,578 award, spanning from January 1, 2025 to December 31, 2028, will enable researchers at the University of Florida to assemble and analyze multi-omic data from large COPD...
- This Project Grant award of $800,679.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support the University of Virginia's research to interrogate the pathogenesis of chronic obstructive pulmonary disease (COPD) using metabolomics and genomics data. The objective is to expand the PredixCan method to incorporate metabolomics data, creating a new tool called MetaBoxCan, in order to extract more comprehensive mechanistic information from...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $708,063 in funding to the University of Virginia for a research project titled "Post-Transcriptional Regulatory Networks in Chronic Obstructive Pulmonary Disease". The goal of the 5-year project is to generate RNA-binding protein (RBP) regulatory networks, identify COPD-specific changes, and characterize the functional consequences of the network changes....
- This federal Project Grant award of $140,403 from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and application of new multi-omic analytical methods to elucidate the shared and divergent biology underlying chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The 5-year research project, conducted by the Harvard T.H. Chan School of Public Health, aims to 1) map conditional...
- This federal Project Grant award, totaling $765,612.15, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research (CFDA 93.837) program. The award supports research to conduct a molecular analysis of airway secretory cells in the context of Chronic Obstructive Pulmonary Disease (COPD), the third leading cause of death in the U.S. and worldwide. The research, taking place at the Research Institute at Nationwide Children's Hospital in Columbus, Ohio,...
- This Project Grant award of $762,867.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the role of the cofilin-1 protein in regulating mitochondrial function and quality control in airway epithelial cells. The research, conducted by The Johns Hopkins University, seeks to understand how the loss of cofilin-1 impacts mitochondrial dynamics and mitophagy, and how these processes contribute to airway epithelial dysfunction in...
- This $116,625 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will characterize clinically relevant phenotypes related to osteoporosis and sarcopenia in chronic obstructive pulmonary disease (COPD). The project will develop automated methods to derive static metrics of spine, vertebrae, and pectoral muscles, as well as dynamic metrics of lung diaphragmatic surface deformation, from chest CT scans. It will then use...
- This federal Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research project at Brigham & Women's Hospital Inc. to better understand changes in the pulmonary vasculature and their relationship to lung parenchyma using advanced CT imaging in patients with pulmonary hypertension and chronic obstructive pulmonary disease (COPD). The $812,189 award, with a project period from May 1, 2025 to...
- This $131,783 federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will fund a study to develop and implement a protocol for biospecimen collections before and after bronchoscopic lung volume reduction (BLVR) procedures in COPD patients. The goal is to identify blood and bronchoalveolar lavage fluid biomarkers associated with COPD phenotypes...
- The National Heart Lung and Blood Institute (NHLBI), via the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $222,750 project grant to the University of Alabama at Birmingham (UAB) to investigate genetic factors that influence susceptibility to frequent exacerbations in African American patients with chronic obstructive pulmonary disease (COPD). The key objectives are to: 1) Examine the interaction between specific variants in immunoglobulin G (IgG) and its...
This federal Project Grant award of $805,921 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to integrate multi-trait, multi-ancestry, and multi-omic data from massive global biobanks to decipher the genetic mechanisms underlying respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma. The award, with a performance period from September 2025 to June 2030, will leverage data from over 2 million participants, including approximately 240,000 COPD cases, 260,000 asthma cases, and 60,000 proteomic profiles, across biobanks such as the All of Us Research Program, Million Veterans Program, UK Biobank, and FinnGen. The project aims to identify shared and distinct genetic risk factors for lung diseases, connect genetic variants to function, and delineate relationships between genetics, environment, and disease risk using multi-omic analyses, with a focus on diverse populations disproportionately affected by respiratory diseases.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $805.9k | 9/3/25 |